Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

March 25th 2025

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

In SCLC, transcription factors have also been found to play a key role in chemoresistance, and differences in expression of transcription factors have been tied to drug sensitivities. | Image credit: Rasi-stock.adobe.com
Examination of FOXP1 in SCLC Yields Potential Strategy Against Chemoresistance

March 20th 2025

Lung cancer illustration | Image credit: SciePro - stock.adobe.com
Use of AI Lets Health System Find Lung Cancer at Early Stages

March 8th 2025

lung cancer | Image credit: Crystal light - stock.adobe.com
Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

March 5th 2025

radiology x-ray lung cancer | Image credit: utah51 – stock.adobe.com
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer

February 17th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

A graphic of a pair of lungs
September 6th 2023

Liquid Biopsy Might Be Useful in the Detection of Colorectal, Lung Cancer

Justina Petrullo
Investigators wanted to analyze the diagnostic performance of methylation-sensitive restriction enzyme digestion followed by sequencing using cell-free DNA and explore the cancer signal origin of the cancer using DNN analyses for colorectal and lung cancers.
A Black couple listens to a health care provider
September 3rd 2023

Elimination of PFTs Might Worsen Disparities for African American Patients With Lung Cancer

Justina Petrullo
Removal of pulmonary function tests (PFTs) might exacerbate disparities for African American patients with lung cancer.
A scientist is adding blood to vials
August 22nd 2023

Certain Immune Cell Types Linked With ICI Response in Patients With NSCLC

Justina Petrullo
Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).
skeleton with lungs highlighted
August 21st 2023

Perspectives on Immunotherapy in the Treatment of Advanced NSCLC: A Stakeholder Interchange Report

graphic of a brain
August 19th 2023

Machine-Learning Models May Help Determine Brain Metastasis Risk in Patients With NSCLC

Justina Petrullo
Patients with non-small cell lung cancer (NSCLC) with a high risk of brain metastases might feasibly be identified through machine-learning models, according to a recent study.
graphic image of a human body showing lungs with cancer
August 17th 2023

Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC

Jordyn Sava
Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.
United States flag patch on army clothing
August 7th 2023

The Process From Referral to LCS Is a Crucial Point Among Veterans

Justina Petrullo
The process from referral to the lung cancer screening (LCS) process is a crucial point for Black veterans and may serve as a point of improvement, according to a study.
Sagun Shrestha, MD
August 6th 2023

Changes to the SCLC Treatment Landscape Stirs Up Hope for Oncologists

Jordyn Sava
In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.
IVBM Logo
August 4th 2023

Emory’s Ticiana Leal, MD, Says Rise in Druggable Targets Boosts Importance of Biomarker Testing in NSCLC

Mary Caffrey
Coverage from the Institute for Value-Based Medicine event in Atlanta, held in partnership with Winship Cancer Institute of Emory University.
a wildfire in a forest
August 2nd 2023

Wildfire Smoke Linked to Worse Survival for Individuals With NSCLC After Surgical Resection

Justina Petrullo
Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.
radiology x-ray lung cancer: © utah51 - stock.adobe.com
July 31st 2023

Subtle Differences in NSCLC Could Help Guide Treatment Strategies

Gwen Mergian
Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).
Image of lung cancer.jpe
July 26th 2023

Risk Prediction Improvements Needed for Former Smokers at High Risk for Lung Cancer

Pearl Steinzor
Prediction models are needed to identify individuals at high risk for lung cancer who are former smokers and for whom low-dose computed tomography screening is not recommended, according to one study.
Person on computer | Image credit: BullRun - stock.adobe.com
July 20th 2023

Study Explores Symptoms, Lived Experiences of Patients With NSCLC Using Social Media

Gianna Melillo
Researchers assessed public posts on websites to better understand the experiences of patients with non–small cell lung cancer (NSCLC).
IV_chemo - Sherry Young - stock.adobe.com.jpe
July 17th 2023

PAPILLON Study Meets Clinical End Point in Patients With EGFR Exon 20 Insertion–Mutated Advanced NSCLC

Pearl Steinzor
Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Lungs
July 15th 2023

Study Identifies Which Patients With SCLC May Benefit Most From SRS

Gianna Melillo
Patients with small cell lung cancer (SCLC) with fewer than 5 brain metastases fared better than those with more than 5 when treated with stereotactic radiosurgery (SRS).
lungcancer.jpe
July 12th 2023

Standardized SIF Reporting, Management Guidelines Needed in LDCT Lung Screening

Pearl Steinzor
A retrospective case series study suggests that standardized guidelines for reporting and managing significant incidental findings (SIFs) in low-dose computed tomography (LDCT) lung cancer screening could help optimize the treatment of patients whose LDCT scans show SIFs.
Lung cancer, 3D illustration and photo under microscope. Light micrograph showing lung adenocarcinoma: © Dr_Microbe - stock.adobe.com
July 6th 2023

Meta-Analysis Shows Certain Antidepressants May Increase Lung Cancer Risk

Jared Kaltwasser
Investigators found no significant impact on survival, however.
Lung cancer awareness red background with white ribbon, alarm clock and stethoscope: © WindyNight - stock.adobe.com
June 29th 2023

Survey Outlines Lung Cancer Survivors’ Views on Telerehabilitation

Gianna Melillo
The majority of patients had prior experience with telemedicine, but none had experience with telerehabilitation.
Searching for New Solutions in Treating EGFR-Mutant NSCLC
June 27th 2023

Searching for New Solutions in Treating EGFR-Mutant NSCLC

Mary Caffrey
Abstracts were presented in a session on metastatic lung cancer on the final day of the 2023 American Society of Clinical Oncology Annual Meeting.
DNA Test for Cancer Screening
June 22nd 2023

ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening

Rose McNulty
A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.
TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC
June 16th 2023

TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC

Kristie L. Kahl
The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).
Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC
June 15th 2023

Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC

Rose McNulty
A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.
ctDNA Tumor Fraction Retains Strong Prognostic Value for Advanced NSCLC
June 9th 2023

ctDNA Tumor Fraction Retains Strong Prognostic Value for Advanced NSCLC

Alana Hippensteele
High circulating tumor DNA (ctDNA) tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades for non–small cell lung cancer (NSCLC), according to research discussed during a presentation at the American Society of Clinical Oncology Annual Meeting.
Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting
June 9th 2023

Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting

Rose McNulty
An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.
Smoking Cessation Associated With Increased Survival Among Patients With Lung Cancer
June 2nd 2023

Smoking Cessation Associated With Increased Survival Among Patients With Lung Cancer

Erin Hunter
Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.
OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023
May 24th 2023

OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.
Doctor, woman with tablet in hands and hologram with medical data, anatomy and lung x ray with overlay. Technology research in healthcare, futuristic and analytics with person and wireless tech: © peopleimages.com - stock.adobe.com
May 22nd 2023

Study Assesses Cost Differences for Robot- vs Video-Assisted Thoracoscopic Surgery in Lung Cancer

Gianna Melillo
Researchers took both the learning curve of the new process and the COVID-19 pandemic into consideration.
Site Logo
May 18th 2023

Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer

Jonathan Kish, PhD, MPH Djibril Liassou, MS John Hartman, PhD Solomon J. Lubinga, PhD Dhruv Chopra, MS Bruce Feinberg, DO
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC
May 17th 2023

Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC

Rose McNulty
Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)
Human Lung model illness, Lung cancer and lung disease. Generative AI: © Royalty-Free - stock.adobe.com
May 16th 2023

Study Examines Incidence, Risk Factors for ICI-Related Pneumonitis in NSCLC

Gianna Melillo
Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.
<12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo